Browse our 650+ Publications​

Latest Publications

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Mateos M, et al.
Lancet Oncology
April 2025
Authors and Affiliates
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Mai Ngo, Eva G Katz, Maria Krevvata, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Meletios A Dimopoulos University Hospital of Salamanca/IBSAL/Cancer Research Center–IBMCC (USAL-CSIC), Salamanca, Spain (M-V Mateos PhD); Cancer Center Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain (Prof J San-Miguel MD); IRCCS Azienda Ospedaliero– Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy (Prof M Cavo MD); Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan (K Suzuki MD); University of Chicago Medical Center, Chicago, IL, USA (Prof A Jakubowiak MD); Department of Hematology, Oncology and Stem Cell Transplantation, Nuremberg General Hospital, Paracelsus Medical School, Nuremberg, Germany (Prof S Knop MD); Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium (Prof C Doyen MD); Champalimaud Centre for the Unknown, Lisbon, Portugal (P Lucio MD); Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary (Z Nagy MD); University Hospital and Masaryk University Brno, Brno, Czech Republic (L Pour MD); Department of Hematology and Cancer Prevention in Chorzów, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Katowice, Poland (S Grosicki MD); Clinica de Tratamento E, Cuiaba, Brazil (A Crepaldi MD); Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria, Terni, Italy (Prof A M Liberati MD); Andrew Love Cancer Centre, University Hospital Geelong, Geelong, VIC, Australia (P Campbell MD); Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (Prof S-S Yoon MD); Medinvest- Institute of Hematology, Tbilisi, Georgia (G Iosava MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); Leicester Royal Infirmary – Haematology, Leicester, UK (M Garg MD); Janssen Research & Development, LLC, Titusville, NJ, USA (M Ngo PhD); Janssen Research & Development, LLC, Raritan, NJ, USA (E G Katz PhD; K Bolyard MS, F Borgsten MD); Janssen Research & Development, LLC, Spring House, PA, USA (M Krevvata PhD, R Carson MD); Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece (Prof M A Dimopoulos MD)

Project EVOLVE: An international analysis of post-immunotherapy lineage switch, an emergent form of relapse in leukemia

Silbert S, et al.
Blood
April 2025
Authors and Affiliates
Sara Silbert (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexander Rankin (Nationwide Children's Hospital, United States) Chloe Hoang (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexandra Semchenkova (Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Regina Myers (Children's Hospital of Philadelphia, United States) Elena Zerkalenkova (Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Russian Federation) Hao-Wei Wang (National Institutes of Health, United States) Alexandra Kovach (Children's Hospital Los Angeles, United States) Constance Yuan (NCI/NIH, United States) Dana Delgado Colon (NCI/NIH, United States) Loic Vasseur (Hôpital Saint Louis, France) Alex Bataller (The University of Texas MD Anderson Cancer Center, United States) Samuel John (Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States) Kaylyn Utley Lyons (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Barbara Friedes (Children's Hospital of Philadelphia, United States) Anna Alonso-Saladrigues (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu. Barcelona. Spain; Institut de Recerca Sant Joan de Déu, Barcelona, Spain; Medicine and Surgery School. University of Barcelona. Barcelona, Spain., Spain) Hisham Abdel-Azim (Loma Linda University school of Medicine, Cancer Center, Children Hospital and Medical Center, United States) Estelle Balducci (Hôpital Necker-Enfants Malades, APHP, France) Ahmed Aljudi (Children's Healthcare of Atlanta, United States) Marie Balsat (Hôpital Lyon sud, Pierre-Bénite, France) D. Biery (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Aghiad Chamdin (Children's hospital of Michigan/Central Michigan University, United States) Bill Chang (OHSU, United States) Raymund Cuevo (Inova Schar Cancer Institute, United States) Barbara De Moerloose (Ghent University Hospital, Belgium) David Dickens (Stead Family Children's Hospital University of Iowa, United States) Ulrich Duffner (Pediatric Bone Marrow Transplantation & Cellular Therapy, Corewell Health Helen DeVos Children's Hospital, 100 Michigan Street NE Grand Rapids, MI 49503, United States) Nicolas Duployez (CHU Lille, France) Firas El Chaer (Division of Hematology and Oncology, Department of Medicine, The University of Virginia, United States) Michelle Elliott (Mayo Clinic, United States) Gabriele Escherich (University hospital Hamburg Eppendorf, Germany) Sneha Fernandes (Great Ormond Street Hospital for Children, London, United Kingdom) Mandi Fitzjohn (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Zhubin Gahvari (University of Wisconsin School of Medicine and Public Health, United States) Stephan Grupp (Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School ofMedicine, University of Pennsylvania, Philadelphia, PA, USA, United States) Rui Rochelle He (Department of Pathology, Inova Fairfax Medical Campus. Inova Health System, Falls Church, VA 22042, United States) Cynthia Harrison (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Christopher Hergott (Brigham and Women's Hospital, United States) Emily Hsieh (Children's Hospital Los Angeles, United States) Annette Kim (University of Michigan, United States) Dennis Kuo (University of California San Diego, United States) Daniel Larson (Mayo Clinic, United States) Benjamin Lee (UC Irvine Health, United States) Thibaut Leguay (Hopital du Haut-Lévèque, France) R. Lindsley (Dana-Farber Cancer Institute, United States) Abhishek Mangaonkar (Mayo Clinic, United States) Kerstin Mezger (Clinic of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, Germany) Holly Pacenta (Cook Children's Medical Center, United States) Jing Pan (Beijing GoBroad Hospital, China) Marlie Provost (HCA HealthONE - Rocky Mountain Hospital for Children, United States) Latika Puri (Loma Linda University Children' Hospitalpital, United States) Sunil Raikar (Emory University, United States) Armando Martinez (National Institutes of Health, United States) Isabella Bristol (National Institutes of Health, United States) Kyle Murphy (National Institutes of Health, United States) Lauren Reiman (Children's Hospital Los Angeles, United States) Michele Redell (Texas Children's Hospital, Baylor College of Medicine, United States) Kelly Reed (University of Virginia School of Nursing, United States) Gabrielle Roth Guepin (Chu nancy, France) Jeremy Rubinstein (Cincinnati Children's Hospital Medical Center, United States) Süreyya Savaşan (Children's Hospital of Michigan, United States) Kristian Schafernak (Phoenix Children's Hospital, United States) Alexandra McLean Stevens (Texas Children's Hospital Downloaded from http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024026655/2367646/blood.2024026655.pdf by guest on 11 April 2025 Baylor College of Medicine, United States) Aimee Talleur (St. Jude Children's Research Hospital, United States) Naomi Torres Carapia (Children's Hospital Los Angeles, United States) Jacques Vargaftig (Institut Curie, France) Anant Vatsayan (Children's National Hospital, United States) Matthias Wölfl (University Hospital Wurzburg, Germany) Liping Zhao (State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China) Susana Rives (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu Barcelona, Spain) Vanessa Fabrizio (University of Colorado Anschutz Medical Campus, United States) Koji Sasaki (The University of Texas MD Anderson Cancer Center, United States) Ibrahim Aldoss (City of Hope National Medical Center, United States) Nicolas Boissel (Hopital Saint-Louis, AP-HP, France) Susan Rheingold (The Children's Hospital of Philadelphia, United States) Kara Davis (Stanford University, United States) Sara Ghorashian (University College London Great Ormond Street Institute of Child Health, United Kingdom) Elad Jacoby (Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, Israel) Alexander Popov (National Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Adam Lamble (Seattle Children's Hospital, United States) Nirali Shah (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States)

Optimal MRD-based endpoint to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Giri S, et al.
Blood
April 2025
Authors and Affiliates
Smith Giri MD, MS1, Binod Dhakal MD2, Natalie S Callander MD3, Eva Medvedova MD4, Kelly Godby MD1, Bhagirathbhai R. Dholaria MD5, Susan Bal MD1, Gayathri Ravi MD1, Saurabh Chhabra MD MS1, Rebecca W Silbermann MD2, Luciano Costa MD PhD1. 1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 2 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 3Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI 4Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 5Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma

Lopedote P, et al.
British Journal of Haematology
April 2025
Authors and Affiliates
Paolo Lopedote1 Geoffrey Shouse1 Sandrine Puverel1 Alexandra Muir1 Carly Roleder1 Peter Sportelli2 Hari Miskin2 Lu Chen1 Tycel J. Phillips1 Alexey V. Danilov1 1City of Hope National Medical Center, Duarte, California, USA 2TG Therapeutics Inc., Morrisville, North Carolina, USA

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma

Shah N, et al.
Journal of Clinical Oncology
March 2025
Authors and Affiliates
Nirav N. Shah, MD, MS1 ; Alfredo S. Colina, BA2 ; Bryon D. Johnson, PhD1; Aniko Szabo, PhD3; Fateeha Furqan, MD1; Tyce Kearl, MD, PhD1 ; Dina Schneider, PhD4 ; Marlenny Vargas-Cortes, BS5 ; Jessica L. Schmeling, BS5 ; Michael B. Dwinell, PhD2; Katie Palen, BS1; Walter Longo, MD1; Peiman Hematti, MD1 ; Anthony E. Zamora, PhD2 ; Parameswaran Hari, MD, MS1 ; Daniel Bucklan, MD6; Ashley Cunningham, MD7; Mehdi Hamadani, MD1 ; and Timothy S. Fenske, MD1 1BMT & Cellular Therapy Program, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 2Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI 3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 4Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD 5Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 6Department of Radiology, Medical College of Wisconsin, Milwaukee,WI 7Department of Pathology, Medical College of Wisconsin, Milwaukee, WI

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Short N, et al.
March 2025
Authors and Affiliates
Nicholas J. Short,1 Ibrahim Aldoss,2 Daniel J. DeAngelo,3 Marina Konopleva,4 Jessica Leonard,5 Aaron C. Logan,6 Jae Park,7 Bijal Shah,8 Wendy Stock,9 and Elias Jabbour1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; 2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; 5Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 6Division of Hematology, Blood and Marrow Transplantation, and Cellular Therapy, Department of Medicine, University of California San Francisco, San Francisco, CA; 7Memorial Sloan Kettering Cancer Center, New York, NY; 8Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and 9Department of Medicine Section of Hematology- Oncology, University of Chicago, Chicago, IL

Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results

Corre J, et al
Blood
March 2025
Authors and Affiliates
Jill Corre,1 Laure Vincent,2 Philippe Moreau,3 Benjamin Hebraud,4 Cyrille Hulin,5 Marie C. Béné,6 Annemiek Broijl,7 Denis Caillot,8 Michel Delforge,9 Thomas Dejoie,10 Thierry Facon,11 Jérôme Lambert,12 Xavier Leleu,13 Margaret Macro,14 Aurore Perrot,4 Sonja Zweegman,15 Thomas Filleron,16 Bastien Cabarrou,16 Niels W.C.J. van de Donk,15 Sabrina Maheo,1 Winnie Hua,17 Jianping Wang,18 Maria Krevvata,18 Veronique Vanquickelberghe,19 Carla de Boer,20 Alba Tuozzo,18 Fredrik Borgsten,21 Melissa Rowe,22 Robin Carson,18 Soraya Wuilleme,6 and Pieter Sonneveld7 1Unité de Genomique du Myélome, IUC- T Oncopole, Toulouse, France; 2Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier, France; 3Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; 4Université de Toulouse, CHU de Toulouse, Service d’Hématologie, Toulouse, France; 5Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France; 6Hematology Biology, University Hospital Hôtel Dieu, Nantes, France; 7Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, The Netherlands; 8Service d’Hematologie, Institut de Cancérologie de Bourgogne (ICB), Dijon, France; 9University of Leuven, Leuven, Belgium; Downloaded from http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024027620/2362739/blood.2024027620.pdf by guest on 27 March 2025 2 10Biochemistry Laboratory, Nantes University Hospital, Nantes, France; 11University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 12Biostatistical Department, Hôpital Saint-Louis, Paris, France; 13University of Poitiers, CHU and Inserm 1313, Poitiers, France; 14Centre Hospitalier Universitaire (CHU) de Caen, Caen, France; 15Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands; 16Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, IUCT-O, Toulouse, France; 17Cytel Inc., Waltham, MA, USA; 18Johnson & Johnson, Spring House, PA, USA; 19Johnson & Johnson, Beerse, Belgium; 20Johnson & Johnson, Leiden, The Netherlands; 21Johnson & Johnson, Raritan, NJ, USA; 22Johnson & Johnson, High Wycombe, UK

Lisocabtagene Maraleucel for Richter’s Transformation—A Case Series

Smith C, et al.
eJHaem
March 2025
Authors and Affiliates
Courtney J. Smith1 Anmol Goyal1 Brian R. Smith1 Dasom Lee2 Alexandria Jensen3 Jonathan Alexander1 Melody Smith1 Matthew Frank1 Saurabh Dahiya1 David Miklos1 Sushma Bharadwaj1 1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA 2Division of Hematology, Stanford University School of Medicine, Stanford, California, USA 3Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Facon T, et al.
Leukemia
February 2025
Authors and Affiliates
Thierry Facon1, Philippe Moreau 2, Katja Weisel 3, Hartmut Goldschmidt 4, Saad Z. Usmani 5, Ajai Chari6, Torben Plesner7, Robert Z. Orlowski 8, Nizar Bahlis 9, Supratik Basu 10, Cyrille Hulin 11, Hang Quach 12, Michael O’Dwyer 13, Aurore Perrot 14, Caroline Jacquet15, Christopher P. Venner16,17, Noopur Raje18, Mourad Tiab19, Margaret Macro20, Laurent Frenzel21, Xavier Leleu 22, Gordon Cook 23, George Wang24, Huiling Pei25, Maria Krevvata24, Robin Carson24, Fredrik Borgsten26 and Shaji K. Kumar 1University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 2Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. 3Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4GMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany. 5Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Icahn School of Medicine at Mount Sinai, New York, NY, USA. 7Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 8Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 10Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK. 11Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 12University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia. 13Department of Medicine/Haematology, NUI, Galway, Republic of Ireland. 14CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France. 15Department of Hematology, University Hospital, Nancy, France. 16Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 17BC Cancer – Vancouver Centre Group, Vancouver, BC, Canada. 18Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 19CHD Vendée, La Roche sur Yon, France. 20Centre Hospitalier Universitaire (CHU) de Caen, Caen, France. 21Hôpital Necker-Enfants Malades, Paris, France. 22CHU Poitiers, Hôpital la Milétrie, Poitiers, France. 23Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. 24Janssen Research & Development, LLC, Spring House, PA, USA. 25Janssen Research & Development, LLC, Titusville, NJ, USA. 26Janssen Research & Development, LLC, Raritan, NJ, USA. 27Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients with Comparable Rates of Minimal Residual Disease Negativity

Kort J, et al.
Clinical Lymphoma Myeloma & Leukemia
February 2025
Authors and Affiliates
Jeries Korta,b,1, Nikolas Naleidc , Frank Oleya , James Ignatz-Hoovera,b, Seunghee Margeviciusd , Pingfu Fud , Ehsan Maleka,b,2, Brenda Coopera,b a. Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH b. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH c. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH d. Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH 1. University of Kansas Medical Center, Kansas City, KS 2. Roswell Park Cancer Institute, Buffalo, NY
Previous Next